Hazlett Burt & Watson Inc. Raises Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Hazlett Burt & Watson Inc. boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 217.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 888 shares of the medical instruments supplier’s stock after buying an additional 608 shares during the period. Hazlett Burt & Watson Inc.’s holdings in Becton, Dickinson and Company were worth $214,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Axxcess Wealth Management LLC increased its stake in Becton, Dickinson and Company by 30.2% in the 1st quarter. Axxcess Wealth Management LLC now owns 11,051 shares of the medical instruments supplier’s stock worth $2,735,000 after buying an additional 2,565 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Becton, Dickinson and Company by 206.5% during the first quarter. SG Americas Securities LLC now owns 46,328 shares of the medical instruments supplier’s stock valued at $11,464,000 after purchasing an additional 31,215 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Becton, Dickinson and Company by 24.0% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 32,175 shares of the medical instruments supplier’s stock worth $7,962,000 after purchasing an additional 6,220 shares during the last quarter. UniSuper Management Pty Ltd lifted its position in shares of Becton, Dickinson and Company by 225.9% in the first quarter. UniSuper Management Pty Ltd now owns 7,775 shares of the medical instruments supplier’s stock worth $1,924,000 after buying an additional 5,389 shares in the last quarter. Finally, Cetera Investment Advisers boosted its stake in Becton, Dickinson and Company by 380.8% during the first quarter. Cetera Investment Advisers now owns 58,923 shares of the medical instruments supplier’s stock valued at $14,580,000 after buying an additional 46,668 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $234.33 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The firm has a market capitalization of $67.73 billion, a P/E ratio of 48.22, a price-to-earnings-growth ratio of 1.75 and a beta of 0.43. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $259.92. The company’s 50-day moving average is $237.52 and its 200 day moving average is $235.10.

Analyst Ratings Changes

Several analysts have recently issued reports on BDX shares. Stifel Nicolaus upped their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Evercore ISI upped their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Raymond James dropped their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.